Epizyme Inc (NASDAQ:EPZM) Receives $16.00 Average Price Target from Brokerages

Share on StockTwits

Epizyme Inc (NASDAQ:EPZM) has earned a consensus rating of “Buy” from the ten research firms that are currently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating and eight have given a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $16.00.

A number of brokerages recently commented on EPZM. BidaskClub raised Epizyme from a “hold” rating to a “buy” rating in a research note on Thursday, November 21st. Zacks Investment Research downgraded Epizyme from a “hold” rating to a “sell” rating and set a $11.00 price objective on the stock. in a research note on Monday, October 21st. HC Wainwright reaffirmed a “buy” rating on shares of Epizyme in a report on Thursday, October 31st. ValuEngine cut Epizyme from a “hold” rating to a “sell” rating in a report on Thursday, November 7th. Finally, Cowen reiterated a “buy” rating and set a $18.00 target price on shares of Epizyme in a research report on Thursday, October 31st.

Several hedge funds and other institutional investors have recently made changes to their positions in EPZM. Metropolitan Life Insurance Co NY lifted its holdings in shares of Epizyme by 33.9% in the 3rd quarter. Metropolitan Life Insurance Co NY now owns 26,206 shares of the biopharmaceutical company’s stock valued at $270,000 after acquiring an additional 6,636 shares during the last quarter. California State Teachers Retirement System boosted its holdings in shares of Epizyme by 1.6% in the 3rd quarter. California State Teachers Retirement System now owns 121,524 shares of the biopharmaceutical company’s stock worth $1,254,000 after purchasing an additional 1,962 shares during the period. Voya Investment Management LLC increased its position in shares of Epizyme by 133.3% during the 3rd quarter. Voya Investment Management LLC now owns 651,683 shares of the biopharmaceutical company’s stock valued at $6,722,000 after purchasing an additional 372,321 shares during the last quarter. California Public Employees Retirement System increased its position in shares of Epizyme by 17.4% during the 3rd quarter. California Public Employees Retirement System now owns 270,445 shares of the biopharmaceutical company’s stock valued at $2,790,000 after purchasing an additional 40,055 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Epizyme by 29.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,564 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 1,262 shares during the period. Hedge funds and other institutional investors own 86.94% of the company’s stock.

EPZM stock traded up $0.14 during mid-day trading on Tuesday, hitting $15.90. The company had a trading volume of 1,040,857 shares, compared to its average volume of 799,504. The company has a 50-day moving average price of $13.51 and a 200 day moving average price of $12.82. Epizyme has a 12-month low of $5.14 and a 12-month high of $17.00. The company has a market capitalization of $1.50 billion, a price-to-earnings ratio of -9.24 and a beta of 2.58. The company has a quick ratio of 10.90, a current ratio of 10.90 and a debt-to-equity ratio of 0.03.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.51) by $0.11. Epizyme had a negative return on equity of 49.38% and a negative net margin of 468.53%. The firm had revenue of $5.72 million during the quarter, compared to analyst estimates of $5.50 million. As a group, analysts expect that Epizyme will post -1.89 EPS for the current year.

Epizyme Company Profile

Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.

Read More: SEC Filing

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.